Director at KORU Medical Systems (KRMD) receives stock grant

Rhea-AI Filing Summary

KORU Medical Systems director Robert Cascella received a stock grant, increasing his direct holdings. He was awarded 3,472 shares of Common Stock as a grant or award at an indicated price of $4.32 per share. Following this compensation-related acquisition, he directly owns 94,584 shares. This is a routine equity award rather than an open-market purchase or sale.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider CASCELLA ROBERT

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	3,472	$4.32	$15K

Holdings After Transaction: Common Stock — 94,584 shares (Direct)

Footnotes (1)

Key Figures

Stock grant size: 3,472 shares Grant price: $4.32 per share Post-transaction holdings: 94,584 shares

3 metrics

Stock grant size 3,472 shares Common Stock grant/award to director on April 1, 2026

Grant price $4.32 per share Transaction price per share for the awarded stock

Post-transaction holdings 94,584 shares Total Common Stock directly owned after the grant

Key Terms

Form 4, non-derivative, grant/award acquisition, beneficial ownership

4 terms

Form 4 regulatory

"INSIDER FILING DATA (Form 4):"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

non-derivative financial

""transaction_type": "non-derivative""

grant/award acquisition financial

""transaction_action": "grant/award acquisition""

beneficial ownership regulatory

""disclaims beneficial ownership" (context in instructions)"

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

CASCELLA ROBERT

(Last) (First) (Middle)

C/O KORU MEDICAL SYSTEMS, INC.

100 CORPORATE DRIVE

(Street)

MAHWAH NEW JERSEY 07430

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
KORU Medical Systems, Inc. [ KRMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	04/01/2026		A		3,472	A	$4.32	94,584	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

The filing of this statement shall not be construed as an admission (a) that the person filing this statement is, for the purposes of Section 16 of the Securities Exchange Act of 1934, as amended, the beneficial owner of any equity securities covered by this statement, or (b) that this statement is legally required to be filed by such person. Power of Attorney has been previously filed.

	/s/ Thomas Adams - Attorney-in-Fact	04/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did KRMD director Robert Cascella report?

Director Robert Cascella reported receiving a grant of 3,472 KRMD common shares. This was recorded as a grant or award acquisition, not an open-market trade, reflecting routine equity-based compensation rather than a discretionary stock purchase or sale.

At what price was the KRMD stock grant to Robert Cascella recorded?

The 3,472-share KRMD stock grant to Robert Cascella was recorded at $4.32 per share. This figure represents the transaction price per share disclosed for the award and helps indicate the valuation used for this compensation-related grant.

How many KORU Medical (KRMD) shares does Robert Cascella hold after the grant?

After receiving the 3,472-share grant, Robert Cascella directly holds 94,584 KRMD common shares. This total reflects his position following the reported transaction and provides context for the size of the award relative to his overall holdings.

Was the KRMD insider transaction a market buy or sell of shares?

The KRMD insider transaction was not a market buy or sell; it was a grant or award acquisition. The Form 4 classifies the action under a grant/award code, indicating routine equity compensation rather than an open-market purchase or disposal of shares.

Does the KRMD Form 4 show any derivative securities activity for Robert Cascella?

The KRMD Form 4 shows no derivative securities activity for Robert Cascella. The transaction involves only non-derivative common stock, and the derivative summary section is empty, indicating no option exercises, conversions, or other derivative transactions in this filing.